PureTech Health plc American Depositary Shares - PRTC STOCK NEWS

PureTech Health (Nasdaq: PRTC) acknowledges the publication of Karuna Therapeutics' EMERGENT-1 Phase 2 trial results for KarXT, aimed at treating schizophrenia, in the New England Journal of Medicine. The trial demonstrated a statistically significant 11.6-point reduction in PANSS total score compared to placebo at Week 5 (p<0.0001). Incidences of side effects were similar in both treatment groups. KarXT is now advancing into Phase 3 development, providing a potential novel therapy for over 21 million people globally affected by schizophrenia.

PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) announces the participation of key executives in the SVB Leerink 10th Annual Global Healthcare Conference on February 26 at 10:00 AM EST. The panel will feature Bharatt Chowrira, George Farmer, and Michael Chen, who will discuss the company's ongoing efforts in developing innovative biotherapeutics for serious diseases. A live webcast of the event will be available for interested stakeholders.

PureTech Health (LSE: PRTC, Nasdaq: PRTC) announced that its Founded Entity, Vor Biopharma (Nasdaq: VOR), successfully closed its IPO, raising approximately $203.4 million by selling nearly 11.3 million shares at $18.00 per share. Following the offering, PureTech retains 3,207,200 shares of Vor, accounting for about 8.6% of Vor's outstanding shares. This capital aims to advance Vor’s engineered hematopoietic stem cell therapies for cancer treatment, bolstering PureTech’s broader pipeline of clinical-stage therapeutics.

PureTech Health (LSE: PRTC, Nasdaq: PRTC) has sold 1 million shares of Karuna Therapeutics (Nasdaq: KRTX) for approximately $118 million via a block trade executed by Morgan Stanley. The company plans to utilize the proceeds to enhance its clinical-stage pipeline. After the sale, PureTech holds about 9% of Karuna's outstanding shares, totaling 2,406,564 shares. The transaction was authorized by shareholders on August 26, 2020, and PureTech will update its financial guidance in its upcoming 2020 Annual Report.

Vedanta Biosciences has appointed Mark Mullikin as the new Chief Financial Officer. Mullikin brings 25 years of experience from roles in finance and investor relations at companies like Editas Medicine and Novartis. His expertise includes raising $700 million in equity capital at Editas. The company is recognized for pioneering a new category of therapies utilizing human microbiome-derived bacteria. Mullikin expressed enthusiasm about joining Vedanta at a critical growth phase, with key clinical trial results expected this year.

PureTech Health (LSE: PRTC, NASDAQ: PRTC) announced the appointment of Mark Mullikin as Chief Financial Officer of its Founded Entity, Vedanta Biosciences. With 25 years of experience in life sciences finance, Mullikin previously raised $700 million in equity capital at Editas Medicine. His expertise includes strategic roles at Novartis and equity analysis at Adage Capital Management. Vedanta is pioneering therapies based on microbiome-derived bacteria for immune-mediated diseases, with significant clinical trial readouts expected this year.

PureTech Health announces that its founded entity, Vor Biopharma, has priced its initial public offering (IPO) of 9,828,017 shares at $18.00 each, raising approximately $176.9 million before expenses. The shares are slated to start trading on Nasdaq under the symbol VOR on February 5, 2021, with the offering expected to close by February 9, 2021. Following the IPO, PureTech will hold 3,207,200 shares of Vor, representing about 9.0% of its outstanding shares.

PureTech Health (LSE: PRTC, Nasdaq: PRTC) has announced the appointment of Bharatt Chowrira, Ph.D., J.D., as an executive director on its Board, effective February 1, 2021. Dr. Chowrira, who has been with the company since March 2017, continues as President and Chief of Business and Strategy. His extensive experience includes prior roles at Synlogic and Auspex Pharmaceuticals. CEO Daphne Zohar expressed confidence in Dr. Chowrira's contributions to advancing PureTech’s clinical pipeline and addressing critical health challenges.

PureTech Health (LSE: PRTC, NASDAQ: PRTC) announces that its Founded Entity, Vor Biopharma, has received FDA clearance for its Investigational New Drug (IND) application for VOR33. This engineered hematopoietic stem cell (eHSC) therapy targets acute myeloid leukemia (AML) patients at high risk of relapse. Vor plans to start a Phase 1/2a clinical trial for VOR33 in the first half of 2021, aiming to improve post-transplant outcomes and patient survival rates. The therapy is designed to be resistant to standard CD33-targeted treatments, marking a significant advancement in AML treatment.